The heart of new ulm: a vision for the future.
Coronary artery disease (CAD) continues to be a leading cause of death in the USA and throughout the world. Allina Health System, with the Minneapolis Heart Institute at Abbott Northwestern, recently announced a long-term study in the city of New Ulm, MN, to reduce risk factors for myocardial infarction and, ultimately, reduce myocardial infarction incidence. To achieve this goal, the focus will be on health promotion interventions and primary and secondary prevention strategies for CAD that are innovative, community-wide, and able to impact individuals at home, at work, in their community, and in their health care settings. Factors considered in selecting this city included the identification of health as a priority by the community, readiness and willingness of the community to change, the ability to provide and deliver systematic care, and partnerships established across multiple disciplines and sectors centered on improved health. The following stakeholders will be engaged: the community, employers, public health, health care, and health plans. Unique aspects of the intervention include centralized healthcare, including an automated medical record; genetic testing; integrated behavioral interventions; social environmental change and social circumstances; health promotion, primary prevention and secondary prevention interventions; advanced diagnostics and imaging; and state-of-the-art therapy.
Boucher
Jackie L
JL
Minneapolis Heart Institute Foundation, 920 East 28th Street, Suite 100, Minneapolis, MN 55407, USA. jboucher@mhif.org
Pereira
Raquel Franzini
RF
Graham
Kevin J
KJ
Pettingill
Richard R
RR
Toscano
James V
JV
Henry
Timothy D
TD
D003153:Community Health Services; D003256:Community Participation; D003695:Delivery of Health Care; D006293:Health Promotion; D006801:Humans; D007348:Insurance, Health; D008910:Minnesota; D009203:Myocardial Infarction / Q000517:prevention & control*; D009786:Occupational Health Services; D011322:Primary Prevention; D011634:Public Health; D055502:Secondary Prevention; D035703:Therapies, Investigational